ALFA Finder| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 7% YoY overall; API revenue grew 6% YoY on volumes. |
|---|---|
| Margins | API gross margins stable at 60%+; consolidated margins dragged by capex. |
| Order book | Multi-year take-or-pay contracts secured for insulin and alternative proteins. |
| Demand visibility | Strong traction in synthetic biology; order book 'over the roof'. |
| Management confidence | Extremely bullish on biotech shifts; confident in H2 FY27 recovery. |
Growth
Core API business grew 6% YoY on volumes; new CDMO/Injectables segments contribute ₹34 Cr in combined costs without revenue.
Outlook
Management guides 20% revenue and 25% EBITDA growth for FY27, backed by Q3/Q4 milestone cashflows.
Risks
Substantial ₹1,000 Cr+ capex remains unmonetized; new business segments face high depreciation and operating expense drag in early FY27.
Earnings Call Transcript filed with NSE, NSE: SYMBIOTEC. Summary written with AI assistance from the document.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,611.00
- Market cap
- ₹10,352 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.
- Call
- Guides 20% growth
Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q2 and H1 FY27 investor release, reporting consolidated Q2 revenue of ₹280 crore and PAT of ₹52 crore. The release also cites a ₹53 crore milestone revenue from a US licensing agreement.
Symbiotec Pharmalab Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹280 Cr (+43%), PAT ₹52 Cr (+169%); H1 revenue ₹498 Cr (+25%), PAT ₹66 Cr (+34%). Capex-led push into DCV injectables and CDMO.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing lists promoter and public holdings with no transaction or corporate event.
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab schedules a 5 November 2026 board meeting to consider unaudited quarterly and half-year results. No amounts are proposed.
Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.